EUVIMED · CrossrefZeitschrift
Journal of Hepatology
ISSN 0168-8278 · Elsevier BV
Neueste Artikel
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma
Regression of liver cirrhosis
MRI-based prediction of very early recurrence within 1 year after resection of HCC: An international cohort study
Reply to: “Agree to disagree; increasing the impact of recommendations formulated through Delphi methodology”
Fibrosis regression in chronic liver disease: The pathologist’s view
Baveno VIII – Advancing consensus in portal hypertension
Liver biopsy confirms precise and efficient correction of SERPINA1 after in vivo Base Editing in a Patient with Alpha-1 Antitrypsin Deficiency
Seladelpar for alkaline phosphatase normalization in primary biliary cholangitis: The IDEAL phase III randomized controlled trial
Senescence induces clonal failure of hepatocyte plasticity and reshapes regenerative lineages
T cells and the bile duct: CD226-NECTIN2 as a druggable axis in immune-mediated cholangiopathy
Advances in the imaging of liver cancer
Surveillance of patients at risk of liver cancer: Expert opinions
Artificial intelligence and personalised medicine in liver cancer
Acute-on-chronic liver failure: A global multisociety consensus on definitions
Reply to: "beyond portal pressure: what does CIRI really predict?" and "can the CIRI model reliably predict cACLD decompensation for clinical adoption?"
Survival outcomes after liver transplantation in acute-on-chronic liver failure: A prospective study
Abnormal left ventricular mass as a prognostic marker for outcomes in infants and children with cirrhosis
Reply to: “Comment on surveillance of patients at risk of liver cancer: Expert opinions”
Reply to: “Statistical pitfalls in interpreting zero HCC risk and HBsAg clearance in the long-term PAGE-B cohort”
Crosstalk along the gut–liver axis in liver disease: Clinical and mechanistic aspects
HBs proteins do not reveal their genomic origin
EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and post-treatment results from a phase III randomized trial
Fusobacterium nucleatum alleviates alcohol-associated liver disease through mannose-mediated elevation of Fbp1 and modulation of gut microbiota
Single-nucleus profiling reveals hepatocyte identity and immune features associated with corticosteroid response in severe alcohol-related hepatitis
A multi-analyte cfDNA-based blood test for early detection of hepatocellular carcinoma
Updates in clinical science: Alcohol-related hepatitis
Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acid
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares
Delphi consensus in primary biliary cholangitis: Collective introspection to set a path forward
Jahrgänge
2026 · 4672025 · 2.5162024 · 2.4002023 · 2.4642022 · 2.2702021 · 5912020 · 2.2122019 · 2.1942018 · 2.2872017 · 2.2362016 · 2.1572015 · 2.1352014 · 2.0862013 · 1.9982012 · 2.0282011 · 1.9082010 · 1.6162009 · 1.5022008 · 1.4132007 · 1.1792006 · 1.1792005 · 1.1732004 · 1.1112003 · 1.1762002 · 1.3272001 · 2.0652000 · 1.1741999 · 4141998 · 1.0861997 · 4391996 · 2951995 · 3151994 · 1.0161993 · 3341992 · 2691991 · 9371990 · 6951989 · 6491988 · 5211987 · 584
EUVIMED